Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-003248-28
    Sponsor's Protocol Code Number:DDD22WATER
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2022-11-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2022-003248-28
    A.3Full title of the trial
    The effect of sparkling water on the systemic pharmacokinetics of paracetamol in elderly
    Het effect van spuitwater op de opname van paracetamol in ouderen
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The effect of sparkling water on the blood concentration of paracetamol in elderly
    Het effect van spuitwater op de opname van paracetamol in ouderen
    A.3.2Name or abbreviated title of the trial where available
    WATER
    A.4.1Sponsor's protocol code numberDDD22WATER
    A.5.4Other Identifiers
    Name:Clinical Trial Center UZ Leuven identifierNumber:S67145
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorKU Leuven - Drug Delivery and Disposition
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportKU Leuven
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationKU Leuven
    B.5.2Functional name of contact pointDrug Delivery and Disposition
    B.5.3 Address:
    B.5.3.1Street AddressGasthuisberg O&N 2 - Herestraat 49 bus 921
    B.5.3.2Town/ cityLeuven
    B.5.3.3Post code3000
    B.5.3.4CountryBelgium
    B.5.6E-mailfritzrobert.harder@kuleuven.be
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name DAFALGAN 500 mg tabletten
    D.2.1.1.2Name of the Marketing Authorisation holderUPSA
    D.2.1.2Country which granted the Marketing AuthorisationBelgium
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDAFALGAN 500 mg tabletten
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNParacetamol
    D.3.9.1CAS number 103-90-2
    D.3.9.3Other descriptive nameAcetaminophen
    D.3.9.4EV Substance CodeSUB09611MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Healthy volunteers, 70+ years of age (administration of an antipyretic, analgesic drug)
    Gezonde vrijwilligers (toediening van een analgetisch, antipyretisch geneesmiddel)
    E.1.1.1Medical condition in easily understood language
    Healthy, elderly volunteers
    Gezonde vrijwilligers
    E.1.1.2Therapeutic area Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the effect of sparkling water instead of tap water on the early absorption of paracetamol in the elderly, as measured by the systemic
    AUC0-30 min after oral intake.
    Beoordelen van het effect van bruiswater in plaats van plat water op de vroege absorptie van paracetamol bij ouderen, zoals gemeten aan de hand van de systemische AUC0-30 min na orale inname.
    E.2.2Secondary objectives of the trial
    To explore the effect of sparkling water instead of tap water on additional pharmacokinetic parameters of paracetamol in the elderly.
    Het effect onderzoeken van bruisend water in plaats van plat water op bijkomende farmacokinetische parameters van paracetamol bij ouderen.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
    2. Male or female aged 70 years or older
    3. No clinically significant abnormalities (as determined by the Principal Investigator)
    4. Must be able to understand the requirements of the study and must be willing to comply with the requirements of the study
    1. Vrijwillige schriftelijke geïnformeerde toestemming van de deelnemer of zijn wettelijk gemachtigde vertegenwoordiger is voorafgaand verkregen aan alle screeningprocedures.
    2. Man of vrouw van 70 jaar of ouder
    3. Geen klinisch significante afwijkingen (zoals bepaald door de hoofdonderzoeker)
    4. Moet in staat zijn de eisen van het onderzoek te begrijpen en moet bereid zijn aan de eisen van het onderzoek te voldoen
    E.4Principal exclusion criteria
    1. Participant has a history of acute/chronic gastrointestinal disease(s), hepatic cirrhosis, renal impairment
    2. Any disorder, which in the Investigator’s opinion, might jeopardise the participant’s safety or compliance with the protocol
    3. Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
    4. Any medication that influences gastric motility
    5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device
    6. HIV, HBV or HCV infection
    7. Donated plasma in the 7 days or blood in the 3 months preceding study drug administration
    8. Inability to communicate well with the Investigator and study staff (i.e., language problem, poor mental development or impaired cerebral function).
    9. Inability to consume the tablets provided in the study
    10. History of alcohol or drug abuse within the past year
    1. Deelnemer heeft een voorgeschiedenis van acute/chronische maagdarmziekte(n), levercirrose, nierinsufficiëntie
    2. Elke aandoening die volgens de onderzoeker de veiligheid van de deelnemer of de naleving van het protocol in gevaar kan brengen
    3. Elke eerdere of gelijktijdige behandeling(en) die de veiligheid van de deelnemer in gevaar kan brengen of die de integriteit van het onderzoek in gevaar kan brengen
    4. Medicijnen die de maagmotiliteit beïnvloeden
    5. Deelname aan een interventieonderzoek met IMP
    6. HIV-, HBV- of HCV-infectie
    7. Gedoneerd plasma in de 7 dagen of bloed in de 3 maanden voorafgaand aan de toediening van studiegeneesmiddelen
    8. Onvermogen om goed te communiceren met de onderzoeker en het studiepersoneel (d.w.z. taalprobleem, slechte mentale ontwikkeling of verminderde hersenfunctie).
    9. Onvermogen om de in de studie verstrekte tabletten te consumeren
    10. Voorgeschiedenis van alcohol- of drugsmisbruik in het afgelopen jaar
    E.5 End points
    E.5.1Primary end point(s)
    - AUC0-30 min (µg.h/mL)
    - AUC0-30 min (µg.h/mL)
    E.5.1.1Timepoint(s) of evaluation of this end point
    At pre dose, 5, 10, 15, 20, 25, 30 min post treatment administration
    Voor de eerste dosis en 5, 10, 15, 20, 25, 30 min na toediening van de behandeling.
    E.5.2Secondary end point(s)
    -AUC0-inf (µg.h/mL)
    -AUC0-t (µg.h/mL)
    -Cmax (µg/mL)
    -tmax (min)
    -AUC0-inf (µg.h/mL)
    -AUC0-t (µg.h/mL)
    -Cmax (µg/mL)
    -tmax (min)
    E.5.2.1Timepoint(s) of evaluation of this end point
    At pre dose, 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 180, 240, 300, 360 and 480 min post treatment administration
    Voor de eerste dosis, 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 180, 240, 300, 360 en 480 min na toediening van de behandeling.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Comparison of the influence of carbonated water and tap water on drug disposition
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 23
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state23
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-12-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-12-12
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-12-08
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:59:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA